Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) is scheduled to release its earnings data after the market closes on Tuesday, August 6th. Analysts expect Ligand Pharmaceuticals to post earnings of $1.10 per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported $3.84 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $3.01. Ligand Pharmaceuticals had a return on equity of 8.52% and a net margin of 79.30%. The business had revenue of $30.90 million during the quarter, compared to the consensus estimate of $27.92 million. During the same period in the previous year, the business earned $1.96 EPS. The business’s quarterly revenue was down 29.8% on a year-over-year basis. On average, analysts expect Ligand Pharmaceuticals to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Ligand Pharmaceuticals Price Performance
LGND traded up $0.15 during trading hours on Tuesday, hitting $108.90. 43,842 shares of the stock were exchanged, compared to its average volume of 148,754. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of 21.03 and a beta of 1.01. The stock has a 50-day simple moving average of $88.18 and a 200-day simple moving average of $79.83. Ligand Pharmaceuticals has a 12 month low of $49.24 and a 12 month high of $111.06.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on LGND
Insider Activity at Ligand Pharmaceuticals
In other Ligand Pharmaceuticals news, Director Nancy Ryan Gray sold 934 shares of the firm’s stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $83.20, for a total transaction of $77,708.80. Following the transaction, the director now owns 5,633 shares of the company’s stock, valued at approximately $468,665.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Ligand Pharmaceuticals news, insider Andrew Reardon sold 10,000 shares of the firm’s stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $83.04, for a total value of $830,400.00. Following the completion of the transaction, the insider now directly owns 22,205 shares in the company, valued at $1,843,903.20. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Nancy Ryan Gray sold 934 shares of the business’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $83.20, for a total transaction of $77,708.80. Following the sale, the director now directly owns 5,633 shares in the company, valued at $468,665.60. The disclosure for this sale can be found here. Insiders have sold a total of 25,403 shares of company stock worth $2,150,882 over the last ninety days. 5.90% of the stock is currently owned by corporate insiders.
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.
Read More
- Five stocks we like better than Ligand Pharmaceuticals
- How to Invest in the Best Canadian StocksĀ
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
- What is the Dogs of the Dow Strategy? Overview and Examples
- Aerospace Stock Fires Up a Solid EPS Beat and Raises Guidance
- What is Forex and How Does it Work?
- Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.